Jane A. Gross Purchases 3,750 Shares of Atyr PHARMA INC (NASDAQ:ATYR) Stock

Atyr PHARMA INC (NASDAQ:ATYR) Director Jane A. Gross acquired 3,750 shares of Atyr PHARMA stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $4.00 per share, with a total value of $15,000.00. Following the purchase, the director now directly owns 9,750 shares of the company’s stock, valued at approximately $39,000. This trade represents a 62.50 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Atyr PHARMA Price Performance

Atyr PHARMA stock traded up $0.04 during mid-day trading on Monday, hitting $4.01. 2,054,474 shares of the company were exchanged, compared to its average volume of 826,408. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The company has a market capitalization of $336.61 million, a P/E ratio of -4.27 and a beta of 0.98. Atyr PHARMA INC has a 12-month low of $1.42 and a 12-month high of $4.66. The business’s 50 day simple moving average is $3.65 and its two-hundred day simple moving average is $3.09.

Atyr PHARMA (NASDAQ:ATYR) last released its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. Analysts forecast that Atyr PHARMA INC will post -0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ATYR has been the subject of a number of research analyst reports. Leerink Partners initiated coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 target price for the company. Cantor Fitzgerald initiated coverage on Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating for the company. Leerink Partnrs raised Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a report on Friday. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $18.60.

Institutional Trading of Atyr PHARMA

A number of hedge funds have recently bought and sold shares of the company. Group One Trading LLC purchased a new position in shares of Atyr PHARMA during the 4th quarter worth $26,000. Alterna Wealth Management Inc. acquired a new position in Atyr PHARMA in the fourth quarter valued at $36,000. Victory Capital Management Inc. purchased a new position in Atyr PHARMA during the fourth quarter worth about $37,000. Raymond James Financial Inc. purchased a new position in Atyr PHARMA during the fourth quarter worth about $39,000. Finally, XTX Topco Ltd acquired a new stake in Atyr PHARMA in the 4th quarter worth about $40,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.